MedTrace Logo

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

NCT00817414 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2021-06-02

Study results available
· View outcomes & findings →

Summary

This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.

Conditions

Interventions

DRUG

LCI699-matching placebo

LCI699-matching placebo oral capsules

DRUG

LCI699

LCI699 oral capsules

Sponsors & Collaborators

  • Great Lakes Drug Development, Inc.

    collaborator INDUSTRY

  • Integrium

    collaborator INDUSTRY

  • Novartis

    lead INDUSTRY

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-14
Primary Completion
2009-08-12
Completion
2009-08-12
FDA Drug
Yes

Countries

  • United States
  • Iceland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00817414 on ClinicalTrials.gov